Acquisitions and Collaborative Agreements (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended							6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013		Jun. 30, 2012	Feb. 14, 2013 SMS Pharmaceuticals Ltd.	Feb. 27, 2013 Agila Specialties	Feb. 27, 2013 Committed Financing Agila Specialties	Feb. 27, 2013 Maximum Agila Specialties	Jun. 30, 2013 Generics Segment		Jun. 30, 2013 Generics Segment SMS Pharmaceuticals Ltd.	Jun. 30, 2013 Biocon Insulin Products Strategic Collaboration	Feb. 12, 2013 Insulin analog Biocon Insulin Products Strategic Collaboration drugs
Business Acquisition [Line Items]
Number of products														3
Research and development expense	$ 111,433,000	$ 94,361,000	$ 237,919,000		$ 175,320,000								$ 20,000,000
Total purchase consideration						32,000,000	1,600,000,000	1,000,000,000
Goodwill acquired			10,781,000	[1]						10,781,000	[1]	10,000,000
Contingent consideration									$ 250,000,000

[1] See Note 4.